Thomson Reuters

Exclusive: Germany OKs Northwest Bio brain cancer drug, shares soar

Share Slideshow
Photographer
MIKE BROWN

A manufacturing associate holds a vial with a DCVax-L label in a Northwest Biotherapeutics laboratory in Memphis, Tennessee in this file photo taken February 21, 2014. REUTERS/Mike Brown/Files

A manufacturing associate holds a vial with a DCVax-L label in a Northwest Biotherapeutics laboratory in Memphis, Tennessee in this file photo taken February 21, 2014. REUTERS/Mike Brown/Files
Close
1 / 3
Photographer
MIKE BROWN

A manufacturing associate holds a vial with a DCVax-L label in a Northwest Biotherapeutics laboratory in Memphis, Tennessee in this file photo taken February 21, 2014. REUTERS/Mike Brown/Files

A manufacturing associate holds a vial with a DCVax-L label in a Northwest Biotherapeutics laboratory in Memphis, Tennessee in this file photo taken February 21, 2014. REUTERS/Mike Brown/Files
Close
2 / 3
Photographer
� Jonathan Ernst / Reuters

Northwest Biotherapeutics CEO Linda Powers sits in her company offices in Bethesda, Maryland, February 22, 2014. REUTERS/Jonathan Ernst

Northwest Biotherapeutics CEO Linda Powers sits in her company offices in Bethesda, Maryland, February 22, 2014. REUTERS/Jonathan Ernst
Close
3 / 3

All Collections

Capturing Boko Haram

Friday, February 27, 2015

All Collections

Photos of the week

Friday, February 27, 2015

All Collections

Leonard Nimoy: 1931 - 2015

Friday, February 27, 2015

All Collections

Milan Fashion Week

Friday, February 27, 2015

All Collections

Pushing out Islamic State

Friday, February 27, 2015

All Collections

The Bush dynasty

Friday, February 27, 2015

All Collections

Westerners fight Islamic State

Friday, February 27, 2015

All Collections

Jihadi John uncovered

Thursday, February 26, 2015